According to GlobalData's Pharma Intelligence Center, Hansoh Pharma's co-development partnership with Silence Therapeutics is the third biggest siRNA-based strategic alliance globally in terms of the deal's overall value since Jan 2020. Hansoh will make a 16-million-dollar upfront payment and Silence Therapeutics is eligible to receive up to 1.3 billion dollars in additional development, regulatory and commercial milestones.